CMS has added a big list of New HCPCS codes which will be effective from 1st of July 2020 on May 13. These new HCPCS codes released on May 13 the July 2020 quarterly update to the HCPCS Level II file. Their are around 61 added new codes to describe healthcare equipment and supplies not identified by CPT codes, as well as nine deleted codes and three revised codes.
Due to the COVID 19 pandemic their has been lot of updates from CMS is last few months. If you have missed any update from Medicare or AMA, you can get the information from below links.
Use of Laboratory Analysis Procedure code 0202U
Use of Hospital OPPS specimen collection HCPCS code C9803
Use of CS and 95 modifier with Telehealth and COVID 19 Testing procedure codes
G codes used for Specimen collection for Covid 19
Coding guidelines for CPT code 87635 for Covid 19
Let us checkout the newly added HCPCS codes with their description which are effective from July 1st 2020.
C1748 Endoscope, single-use (i.e. disposable), upper gi, imaging/illumination device (insertable)
C1849 Skin substitute, synthetic, resorbable, per square centimeter
C9059 Injection, meloxicam, 1 mg
C9061 Injection, teprotumumab-trbw, 10 mg
C9063 Injection, eptinezumab-jjmr, 1 mg
C9122 Mometasone furoate sinus implant, 10 micrograms (sinuva)
C9759 Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed
C9760 Non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
C9762 Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging
C9763 Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging
C9764 Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed
C9765 Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed
C9766 Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed
C9767 Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen source
G2025 Payment for a telehealth distant site service furnished by a rural health clinic (RHC) or federally qualified health center (FQHC) only
G2170 Percutaneous arteriovenous fistula creation (AVF), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performed
G2171 Percutaneous arteriovenous fistula creation (AVF), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, wen performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performed
J0223 Injection, givosiran, 0.5 mg
J0591 Injection, deoxycholic acid, 1 mg
J0691 Injection, lefamulin, 1 mg
J0742 Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
J0791 Injection, crizanlizumab-tmca, 0.5 mg
J0896 Injection, luspatercept-aamt, 0.25 mg
J1201 Injection, cetirizine hydrochloride, 0.5 mg
J1429 Injection, golodirsen, 10 mg
J1558 Injection, immune globulin (Xembify), 100 mg
J3399 Injection, Onasemnogene abeparvovec-xioi, per treatment, up to 5×1015 vector genomes
J7169 Injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg
J7204 Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu
J7333 Hyaluronan or derivative, visco-3, for intra-articular injection, per dose
J9177 Injection, enfortumab vedotin-ejfv, 0.25 mg
J9198 Injection, gemcitabine hydrochloride, (infugem), 100 mg
J9246 Injection, melphalan (evomela), 1 mg
J9358 Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
Q4227 Amniocore, per square centimeter
Q4228 Bionextpatch, per square centimeter
Q4229 Cogenex amniotic membrane, per square centimeter
Q4230 Cogenex flowable amnion, per 0.5 cc
Q4231 Corplex P, per cc
Q4232 Corplex, per square centimeter
Q4233 Surfactor or nudyn, per 0.5 cc
Q4234 Xcellerate, per square centimeter
Q4235 Amniorepair or altiply, per square centimeter
Q4236 Carepatch, per square centimeter
Q4237 Cryo-cord, per square centimeter
Q4238 Derm-maxx, per square centimeter
Q4239 Amnio-maxx or amnio-maxx lite, per square centimeter
Q4240 Corecyte, for topical use only, per 0.5 cc
Q4241 Polycyte, for topical use only, per 0.5 cc
Q4242 Amniocyte plus, per 0.5 cc
Q4244 Procenta, per 200 mg
Q4245 Amniotext, per cc
Q4246 Coretext or protext, per cc
Q4247 Amniotext patch, per square centimeter
Q4248 Dermacyte amniotic membrane allograft, per square centimeter
Q5119* Injection, Rituximab-pvvr, biosimilar, (Ruxience), 10 mg
Q5120* Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg
Q5121 Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
U0003 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R
U0004 2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R
References:
HCPCS Level II changes effective from July 1st
